<DOC>
	<DOCNO>NCT00383708</DOCNO>
	<brief_summary>The main aim study assess efficacy co-administration lanreotide Autogel 120 mg ( administered via deep sub-cutaneous injection every 28 day ) pegvisomant ( administer 40 120 mg per week via sub-cutaneous injection give twice week ) IGF-1 level 28 week acromegalic patient . The primary endpoint percentage acromegalic patient normalise ( age sex adjust ) IGF-1 level end co-treatment period .</brief_summary>
	<brief_title>Lanreotide Autogel Pegvisomant Combination Therapy Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>The patient must documentation support diagnosis acromegaly , include elevate GH and/or IGF1 level The patient treat pegvisomant , IGF1 level remain ULN treat somatostatin analogue , daily basis least 3 month normal ( age sex adjust ) IGF1 level , IGF1 level upper limit normal ( ULN ) treatment pegvisomant 30 mg per day , OR patient treat lanreotide Autogel octreotide LAR least 6 month include 3 month high market dose serum IGF1 level ULN , 28 day last injection At end runin period , The patient serum IGF1 level 1.2 x ULN , serum IGF1 level ULN 1.2 x ULN serum GH nadir &gt; 1 Âµg/L ( assess OGTT ) , 28 day 3rd injection lanreotide Autogel 120 mg OR patient diabetic serum IGF1 level 1.2 ULN , 28 day 3rd injection lanreotide Autogel 120 mg The patient undergone pituitary surgery radiotherapy within 6 month prior study entry , anticipate do study The patient already treat somatostatin analogue associate GH antagonist The patient receive dopamine agonist within 6 week prior study entry The patient abnormal hepatic function study entry ( define AST , ALT , GGT , alkaline phosphatase , prothrombin time total bilirubin 2 ULN ) The patient risk pregnancy lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>